Pharmaceutical Research Transparency Act of 2022
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Apr 7, 2022)
Pharmaceutical Research Transparency Act of 2022
This bill requires the disclosure of costs associated with clinical trials and pharmaceutical research and development.
Specifically, the National Institutes of Health must create a publicly available repository of cost data from certain clinical trials that test the efficacy of drugs, biological products, and devices in human subjects. For each applicable trial, the registry must, among other information, include the total and per patient cost of the trial, as well as costs for personnel, health care services, and other categories of expenditures. Information must be added to the registry within one year of the trial's completion.
The bill also requires drug manufacturers to include their research and development expenditures for drugs and biological products in annual disclosures made to the Securities and Exchange Commission.
What just happenedApr 8, 2022
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseApr 7, 2022
- Apr 8, 2022Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Apr 7, 2022IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Financial Services Committee - Apr 7, 2022IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Apr 7, 2022IntroReferralIntro-H
Introduced in House
- Apr 7, 2022IntroReferral1000
Introduced in House